Univercells

Founded in 2013 in Brussels, Univercells develops bioprocess intensification systems for the pharmaceutical and vaccine manufacturing industry. The company's technology concentrates and simplifies upstream bioprocessing, enabling smaller manufacturing footprints, lower capital costs, and faster production cycles for viral vectors, vaccines, and biologics.

Univercells has reached Scale-Up Stage and serves clients in both established pharma companies and newer mRNA and cell-gene therapy manufacturers. Its bioprocess platforms are particularly relevant for low- and middle-income country vaccine manufacturing, where smaller, cheaper facilities can improve access to production capacity.

The Brussels base and the company's trajectory connect it to the Belgian biotech ecosystem alongside Quantoom Biosciences in Wallonia and Ziphius Vaccines in Ghent, forming a notable RNA and bioprocess technology cluster.